Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.34 |
| ▸ | POLRMT | O00411 | 1/20 | 0.33 |
| ▸ | ADK | P55263 | 4/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25977055 | 1.00 | FGFR1 (0.35) | FGFR1CYP3A4CYP2D6POLRMTADK | |
| SCHEMBL25977030 | 1.00 | FGFR1 (0.35) | FGFR1CYP3A4CYP2D6POLRMTADK | |
| SCHEMBL24407380 | 0.98 | FGFR1 (0.33) | FGFR1CYP3A4CYP2D6POLRMTADK | |
| SCHEMBL24407351 | 0.98 | FGFR1 (0.33) | FGFR1CYP3A4CYP2D6POLRMTADK | |
| SCHEMBL24407381 | 0.98 | FGFR1 (0.33) | FGFR1CYP3A4CYP2D6POLRMTADK | |
| SCHEMBL24407343 | 0.93 | CYP3A4 (0.37) | CYP3A4POLRMTADK | |
| SCHEMBL24407356 | 0.93 | CYP3A4 (0.37) | CYP3A4POLRMTADK | |
| SCHEMBL24407404 | 0.93 | CYP3A4 (0.37) | CYP3A4POLRMTADK | |
| SCHEMBL24407405 | 0.93 | CYP3A4 (0.37) | CYP3A4POLRMTADK | |
| SCHEMBL24305055 | 0.92 | AKT1 (0.36) | FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025932-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2024-01-25 | — | — | US | disclosed |
| US-11773122-B2 | Phospholipid compounds and uses thereof | GILEAD SCIENCES. INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20220081455-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2022-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220081455-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | PHOSPHO1, SGMS2, SGMS1 | FGFR1 4843/4885CYP3A4 2243/4885CYP2D6 2632/4885 |
| US-20240025932-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | PHOSPHO1, SGMS2, SGMS1 | FGFR1 4843/4885CYP3A4 2243/4885CYP2D6 2632/4885 |
| US-11773122-B2 | Phospholipid compounds and uses thereof | PHOSPHO1, SGMS2, SGMS1 | FGFR1 4843/4885CYP3A4 2243/4885CYP2D6 2632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.